Advertisements

Метизол

Quick links to important sections

Метизол

Advertisements
Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Метизол

Methimazole (known by the brand name Tapazole in some regions and as Thiamazole elsewhere) is a prescription medication primarily used to treat hyperthyroidism, a condition characterized by the thyroid gland producing excessive amounts of thyroid hormone.

Quick Facts

  • Drug Class: Antithyroid agent (Thionamide)
  • Primary Use: Management of hyperthyroidism, including Graves' disease.
  • Mechanism: Inhibits the synthesis of thyroid hormones T4 and T3 in the thyroid gland.
  • Availability: Oral tablet, available by prescription only.

Mechanism of Action and Clinical Use

Methimazole belongs to the thionamide class of drugs. It works by interfering with an enzyme called thyroid peroxidase (TPO), which is essential for the production of the thyroid hormones thyroxine (T4) and triiodothyronine (T3). By blocking this process, Methimazole reduces the overall circulating level of thyroid hormones, gradually alleviating the symptoms of an overactive thyroid. However, it does not inactivate hormones that are already formed and stored in the body, meaning that the full therapeutic effect may take several weeks to become noticeable.

The medication is often indicated for patients diagnosed with Graves' disease or toxic multinodular goiter, especially when surgery or radioactive iodine therapy are not considered appropriate treatment options. It may also be used to help reduce hyperthyroid symptoms in preparation for thyroidectomy (surgical removal of the thyroid gland) or radioactive iodine treatment.

Regulatory References

  1. hyperthyroidism, a condition characterized by the thyroid gland producing excessive amounts of thyroid hormone
  2. Inhibits the synthesis of thyroid hormones T4 and T3 in the thyroid gland
Advertisements

What side effects are possible with Метизол?

Possible side effects and safety information

The safety profile of Methimazole (Метизол) is organized in official regulatory documents based on the frequency and severity of reported adverse reactions.


Adverse Reactions and System Groupings

Adverse reactions are classified according to the body system affected. Common, usually less serious, effects are predominantly related to Skin and Subcutaneous Tissue Disorders, manifesting as rash, pruritus (itching), or urticaria, along with minor Gastrointestinal Disorders such as nausea or stomach upset. These minor effects are often more prominent at the initiation of therapy.

Serious adverse reactions are rare but critical. Regulatory labels highlight events related to Blood and Lymphatic System Disorders, most notably agranulocytosis (a severe drop in white blood cells), and Hepatobiliary Disorders, including severe hepatic failure (liver damage). Agranulocytosis is most frequently reported during the first two to three months of treatment.


Safety Considerations

The official labeling notes specific safety restrictions and population-specific risks. The medication is generally contraindicated in individuals with a history of agranulocytosis following prior treatment with thionamides. Use during the first trimester of pregnancy is associated with the potential for fetal harm, including rare birth defects such as aplasia cutis congenita, as the drug readily crosses the placental barrier. Additionally, Methimazole is excreted into breast milk, which is a constraint noted in the official prescribing information.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

A documented overdose of Methimazole (Метизол) is officially described to present with a specific cluster of clinical signs and symptoms. These regulator-listed manifestations include nausea, vomiting, epigastric distress, headache, fever, joint pain (arthralgia), pruritus (itching), and swelling (edema).

Overexposure is associated with severe, life-threatening outcomes defined in regulatory labeling. These include critical blood disorders, such as aplastic anemia (pancytopenia) and agranulocytosis, which are noted to potentially manifest within hours to days. Less frequent, yet documented, severe outcomes involve the liver and kidneys (hepatitis and nephrotic syndrome), as well as central nervous system effects (neuropathies or stimulation/depression) and severe skin reactions (exfoliative dermatitis).

When to Seek Immediate Help

Urgent medical attention is strictly required when specific severe symptoms occur. Immediate emergency services must be contacted if the individual has collapsed, experienced a seizure, exhibits trouble breathing, or cannot be awakened, according to official governmental guidance. A certified Poison Control Center is also a listed resource for current management information.

In the event of overexposure, official guidance dictates that appropriate symptomatic and supportive treatment should be initiated. Regulatory documentation notes that no specific information is available regarding a median lethal dose or a designated antidote, placing the focus on patient support and monitoring.

Advertisements

Therapeutic Uses of Метизол

What Метизол Treats: Main Uses and Benefits

Метизол (Methimazole) is used for easing certain distressing symptoms associated with hyperthyroidism, a condition where the thyroid gland produces an excess of hormones. It is generally applied in situations involving certain distressing symptoms linked to heightened physiological activity. It is commonly used across conditions presenting with acute episodes, such as Graves' disease and toxic multinodular goiter.

Symptom Relief and Stabilization

This medication helps manage symptom clusters that may become intense or disruptive, such as rapid heartbeat (palpitations), noticeable tremor, excessive sweating, and heightened anxiety that interfere with daily functioning. It assists with moderating the underlying condition and contributes to improved comfort during periods of heightened symptoms.

It is also relevant in clinical settings that involve acute or unstable symptom patterns, such as those that precede surgery or therapy. It is useful in scenarios where symptoms escalate temporarily, supporting the patient during difficult episodes by easing distress.


Quick Fact: Relief for Heightened Physiological Activity

The medication is commonly used when symptoms create noticeable physiological strain, assisting with stabilizing the body's overactive state.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Methimazole is generally approved for use in adults and pediatric patients (children and adolescents) for the management of hyperthyroidism. The official regulatory labeling strictly defines populations for whom use is prohibited or restricted.

Contraindications and Restrictions

The medicine is contraindicated in patients with known hypersensitivity to the drug or any component, and in individuals with a history of severe hematologic conditions such as agranulocytosis or aplastic anemia. Use must be discontinued upon the emergence of ANCA-positive vasculitis or clinically significant evidence of liver abnormality.

Population Group Official Eligibility Status
Pregnancy (First Trimester) Not Recommended (Restricted use)
Pregnancy (Later Trimesters) Conditional use (Requires lowest effective dose)
Lactating Women Contraindicated (Per some regulatory labels)

Caution is mandated for patients with existing hepatic dysfunction or other blood/bone marrow disorders. Data are generally insufficient to establish relative safety or efficacy in the geriatric patient population.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Methimazole's interaction profile is primarily defined by the patient's change in thyroid status (transition to euthyroid state) and specific pharmacodynamic effects on co-administered medications, as documented in regulatory information.

Documented Interactions

The following clinically significant interactions have been officially identified:

Interacting Substance/Class Mechanism/Effect Stated in Label
Oral Anticoagulants (e.g., Warfarin) Increased anticoagulant activity due to potential inhibition of vitamin K activity.
Beta-Adrenergic Blockers (e.g., Propranolol) Decreased clearance of the beta-blocker upon transition to euthyroid state.
Digitalis Glycosides (e.g., Digoxin) Increased serum digitalis levels upon transition to euthyroid state.
Theophylline Decreased clearance of theophylline upon transition to euthyroid state.
Myelosuppressive Agents Increased risk of myelotoxicity (e.g., agranulocytosis) when co-administered.

Procedural and Population Notes

The altered clearance of drugs like beta-blockers and digitalis is specifically noted to occur after the hyperthyroid patient achieves a normal thyroid status (euthyroid). When used during pregnancy, methimazole is documented to cross the placental barrier and can cause fetal goiter and cretinism, requiring careful dosage management to prevent this population-specific interaction.

Advertisements

Mechanism of Action

Enzyme Inhibition: Blocking Thyroid Hormone Synthesis

Метизол (Methimazole) acts as a direct, reversible inhibitor of the enzyme Thyroid Peroxidase (TPO), which is essential for thyroid hormone synthesis. This molecular interaction prevents two critical steps: the iodination of tyrosine residues on thyroglobulin and the subsequent coupling of iodotyrosines. This blockade halts the creation of new Thyroxine (T4) and Triiodothyronine (T3) hormones.


Pathway Modulation and Physiological Effect

The synthesis blockade triggers a mechanistic cascade where the overall level of circulating T4 and T3 gradually falls as existing stores are metabolized. This decrease in hormonal signaling within the endocrine axis results in a systemic reduction of the metabolic rate's hormonal drive, influencing the basal metabolic rate. Furthermore, the reduction in thyroid hormones lessens their potentiating effect on beta-adrenergic receptor sensitivity in target tissues, particularly within the cardiovascular system, which influences the heart rate and thermal regulation process.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Methimazole (Метизол)

Methimazole is administered orally and must be taken strictly as prescribed to maintain a consistent therapeutic level in the blood. The total daily dosage is typically divided and given in three separate doses at approximately eight-hour intervals. Taking the medicine with food or milk may help mitigate stomach upset.

Dosing and Frequency

Patient Group Initial Daily Dosage (Typically Divided) Maintenance Daily Dosage
Adults 15 mg to 60 mg (based on severity) 5 mg to 15 mg
Pediatric 0.4 mg/kg of body weight Approximately 0.2 mg/kg of body weight

The initial adult dose is 15 mg for mild hyperthyroidism, 30 mg to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, all divided into three doses. The pediatric dosage must be determined by the prescriber based on body weight.

Procedural and Missed Dose Instructions

  • Administration: The oral tablet is to be taken at evenly spaced times, usually every eight hours, to ensure the medicine works effectively.
  • Preparation: No preparation steps, such as dilution or reconstitution, are required for the oral tablet form.
  • Missed Dose: If a dose is missed, take it as soon as possible. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. Do not double doses to make up for a missed one.

Important Procedural Note

Do not take more of the medicine, do not take it more often, and do not take it for a longer period than the prescriber ordered. Close surveillance by a healthcare professional is essential during therapy.

Advertisements

Recent Clinical Evidence

Метизол: Recent Clinical Evidence

Evidence for use in Hyperthyroidism (Overactive Thyroid)

Research examining the use of Метизол for hyperthyroidism—a condition characterized by functional imbalance—has focused on studies exploring how symptoms change over time and outcomes related to systemic or functional imbalance. Clinical trials monitored outcomes reflecting daily functioning and how symptoms evolved in the observed populations. Findings describe patterns observed in these studies, which often focused on episodes where symptoms become more noticeable. While short-term use was studied, certainty remains low regarding long-term outcomes after the medication is stopped, and comparative evidence against every other available approach is lacking.

Evidence for use in Preparation for Thyroid Surgery or Radioactive Iodine Therapy

Метизол was evaluated in studies as a treatment given before patients undergo thyroid gland surgery or receive radioactive iodine therapy. This application was applied in research contexts involving fluctuating or unstable symptoms of hyperthyroidism. The research examined temporary physiological imbalance in these patients, and data show patterns related to the temporary physiological states measured prior to definitive treatment. However, the specific optimal duration for this preparatory use is not fully established, and there is limited information for long-term outcomes following the procedure.

Long-term Studies and Follow-up

Research has explored the patterns observed when Метизол was studied for extended periods. Studies monitored the durability of the response—meaning how long the measured effects lasted during continuous use and after treatment was stopped. The available evidence suggests patterns related to how symptoms evolved in the observed populations; however, long-term effects are not fully established, and there is limited information for long-term outcomes due to limited follow-up durations in many core studies.

Evidence in Special Populations

Research describes patterns observed when Метизол was studied for specific groups. Studies focusing on children monitored outcomes related to systemic imbalance, but sample sizes were modest and data for certain groups remain insufficient. Evidence is particularly limited for use in pregnancy-related populations, and certainty remains low. Studies in older adults and individuals with co-existing health conditions show mixed findings, meaning subgroup findings are uncertain and more data is needed to understand potential differences in how these groups may be observed to respond.

What is Still Uncertain about Метизол

Current research highlights what is known — and what is still uncertain. Areas where more research is needed include understanding inconsistent findings and exploring why certain patients experience cycles of stability and flare-ups. It is not yet clear whether studies can predict long-term patterns, and factors that influence long-term outcomes are not fully established. Data for certain groups remains insufficient, meaning comparative evidence is lacking to fully understand how Метизол was observed in comparison to other therapies across all types of patients and conditions.

Key Studies & References

  1. Methimazole Tablets, USP - DailyMed (FDA-Approved Prescribing Information)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Метизол (FAQ)

Q: What does the term 'hyperthyroidism' mean in simple language?

Official sources describe hyperthyroidism as a condition where the thyroid gland produces more thyroid hormones than the body needs. In simple terms, it is referred to as an overactive thyroid.

Q: Is Метизол the same as other medicines for the same condition?

The drug belongs to a class of medicines known as Thionamide antithyroid agents. Official communications often compare it to other drugs in the same class, such as Propylthiouracil, mainly to highlight differences in their respective risk profiles, particularly regarding use during pregnancy.

Q: Is it common to switch from another thyroid medication to Метизол?

Official recommendations often indicate that Methimazole is the preferred agent for initial treatment compared to other drugs in its class, such as Propylthiouracil. Switching to Methimazole is sometimes recommended for patients who cannot tolerate an alternative medication.

Q: What are the typical initial expectations for the patient's feeling after starting Метизол?

Based on clinical information, the full therapeutic effect of the medicine can take anywhere from a few weeks to several months to become noticeable. While minor side effects like nausea are often experienced, these are sometimes reported to improve within the first two weeks of starting treatment.

Q: How long is the typical treatment period with Метизол?

The typical treatment period is highly variable and depends on the specific condition being treated. For patients seeking remission, treatment may last for one to two years. Official information also notes that some individuals, such as certain elderly patients, may require long-term or even lifelong therapy.

Q: Can Метизол cause long-term side effects?

Regulatory documents list certain side effects that may occur over time, such as hair loss or joint pain. In addition, treatment with this medicine can sometimes lead to hypothyroidism, which is when the thyroid produces too little hormone. A healthcare provider typically conducts regular monitoring to track these effects.

Q: Is Метизол known to cause hair loss?

Official safety information lists abnormal hair loss as a possible side effect associated with the use of the medication.

Q: Can Метизол affect weight?

Changes in weight are reported in the official side effects listing as a potential effect of the medicine. This includes reports of unusual weight gain or loss of appetite and weight as the body's thyroid hormone levels shift during treatment.

Q: Is it normal to feel tired when starting Метизол?

Official safety information lists drowsiness as a common side effect of the medication. However, unusual tiredness or weakness are also symptoms reported in association with low white blood cell count, liver issues, or developing hypothyroidism, and should be reported to a healthcare provider.

Q: What does 'potential for agranulocytosis' mean in relation to Метизол?

Agranulocytosis is a rare but critical adverse effect noted in regulatory warnings. This condition is a severe drop in the body’s white blood cell count, which makes the body less able to fight off infection. Regulatory information states that signs of infection, such as a fever or sore throat, should be reported promptly to a healthcare provider.

Q: Why is regular blood testing needed while on Метизол?

According to official product information, regular blood tests are essential for two main reasons. They are used to monitor thyroid hormone levels for dose titration purposes, as well as to screen for rare but serious side effects, such as a drop in white blood cell count or signs of liver problems.

Q: How is the effectiveness of Метизол measured?

The effectiveness of the medicine is primarily monitored by frequently checking thyroid hormone levels in the blood. The checks are performed for dosage titration and to confirm the desired effect on thyroid hormone production.

Q: Is Метизол generally well-tolerated by patients?

Official drug descriptions note that while common side effects like rash or upset stomach may occur, the medication is generally considered effective for its intended use. Patients should be aware of the rare risk of serious adverse reactions, such as a severe drop in white blood cells.

Q: Can Метизол affect blood pressure?

Official drug summaries state that Methimazole has been associated with some reports of blood vessel problems. Although not a direct effect on blood pressure, these issues may cause related health problems.

Q: Is Метизол safe for people with existing kidney problems?

Official safety information advises caution for people who have existing kidney disease. Patients with this condition may be at a greater risk for experiencing certain side effects.

Q: Can men and women use Метизол equally?

Regulatory guidance focuses on the specific risks and warnings for use during pregnancy and lactation, which apply to women. The official information does not list any general differences in the drug's efficacy or non-reproductive safety profile for men versus women.

Q: What are the official safety classifications for Метизол?

Official regulatory documents indicate that the drug readily crosses the placental barrier and has been associated with the potential for fetal harm, including congenital malformations. This leads to restricted use and a recommendation for alternative therapies during the first trimester of pregnancy.

Q: Does Метизол have a boxed warning in official documents?

Methimazole itself does not have an FDA Boxed Warning in its official labeling. However, regulatory bodies issued a Boxed Warning for the related antithyroid drug Propylthiouracil (PTU) due to the risk of severe liver injury.

Q: Is there a risk of the condition returning after stopping Метизол?

Official prescribing information indicates that for specific conditions, such as toxic adenoma or toxic multinodular goiter, discontinuing the medication is noted to result in a relapse of the hyperthyroidism. The potential for the condition to return should be discussed with a specialist.

Q: Is it okay to drink alcohol while using Метизол?

Official safety summaries advise patients to avoid drinking alcohol while using Methimazole. Alcohol consumption may increase the risk of developing liver problems and may also raise the risk of severe side effects like agranulocytosis.

Q: Does Метизол interact with common pain relievers?

Official drug interaction checkers list certain common pain relievers, such as aspirin (in various forms), with a low or unknown clinical significance. Because interactions can be complex, information suggests discussing the use of any specific pain relievers with a healthcare professional.

Q: Does Метизол interact with birth control pills?

Patients who use oral contraceptives are advised to inform their healthcare provider. Hormonal birth control pills may affect overall thyroid hormone levels in the body, which can require ongoing monitoring and potential adjustment of the Methimazole dosage.

Q: Can Метизол be taken with other maintenance medications?

Regulatory summaries advise patients to inform their healthcare provider about all prescription and over-the-counter medicines, vitamins, and supplements they are currently using. This is necessary because Methimazole may interact with certain other drugs, which can affect their performance.

Q: What common vitamins or minerals are known to interact with Метизол?

Official safety guidelines recommend that patients inform their healthcare provider about all vitamins and minerals they are taking. This is necessary because of the potential for interactions with the medication.

Q: Does Метизол have any known interactions with herbal supplements?

Official safety guidelines recommend that patients inform their healthcare provider about all herbal products and other supplements they are taking due to potential interactions.

Q: What kind of foods or supplements should I be aware of when using Метизол?

According to available drug safety information, there are no known interactions between Methimazole and specific foods or drinks. The medicine may be taken with food or milk to help with stomach upset, as described in administration guidelines.

Q: Can Метизол be crushed or split if it is a tablet?

Regulatory guidance advises against breaking or crushing the tablets. Official warnings on safe drug handling advise maintaining the tablet's integrity to prevent unintentional drug exposure and potential loss of effectiveness, unless specifically directed by a healthcare professional.

Q: What is the half-life of Метизол?

Pharmacokinetic data, which describes how the body handles the drug, indicates that the elimination half-life of Methimazole in the plasma is typically reported to be in the range of 3 to 5 hours in adults.

Q: Are there common misunderstandings about how Метизол should be used?

Official regulatory guidance emphasizes that the medication must be taken only as directed by the prescriber. It is important for patients not to take more of the drug or take it more often than prescribed, which can lead to potential overdose or serious side effects.

Advertisements

How should Метизол be stored and disposed of?

How to Store and Dispose of Methimazole

Methimazole tablets must be stored at controlled room temperature, specifically between 15 to 30 C (59 to 86 F). The medication must be dispensed and kept in a tight, light-resistant container and the container must remain tightly closed to maintain its quality. A mandatory safety requirement is to keep the tablets out of the reach of children.


Disposal Instructions

Unused or expired Methimazole should not be flushed down the toilet. The preferred disposal method is through an official drug take-back program. If this is unavailable, the medicine should be removed from its container, mixed with an undesirable substance (like dirt or coffee grounds), sealed in a bag, and then discarded in the household trash according to government guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Метизол found in:

A-Z Index: